26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

      Science (New York, N.Y.)

      Animals, Antineoplastic Agents, chemistry, pharmacology, Benzamides, Catalytic Domain, Crystallography, X-Ray, Enzyme Activation, Enzyme Inhibitors, Humans, Mice, Models, Molecular, Phosphorylation, Piperazines, Protein Conformation, Proto-Oncogene Proteins c-abl, antagonists & inhibitors, metabolism, Pyrimidines, Recombinant Fusion Proteins, Structure-Activity Relationship

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML). A small-molecule inhibitor of Abl (STI-571) is effective in the treatment of CML. We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571. Critical to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated. The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases. These results suggest that compounds that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.

          Related collections

          Author and article information

          Journal
          10988075

          Comments

          Comment on this article